For the year ending 2025-12-31, TDAC has $181,696,776 in assets. $6,581,573 in debts. $29,787 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash | 29,787 | |||
| Prepaid expenses | 9,678 | |||
| Total current assets | 39,465 | |||
| Marketable securities held in trust account | 181,657,311 | |||
| Total assets | 181,696,776 | |||
| Accounts payable and accrued expenses | 162,311 | |||
| Due to sponsor | 106,762 | |||
| Promissory note - related party | 200,000 | |||
| Accrued offering costs | 75,000 | |||
| Total current liabilities | 544,073 | |||
| Deferred underwriting fee | 6,037,500 | |||
| Total liabilities | 6,581,573 | |||
| Class a ordinary shares subject to possible redemption, 0.0001 par value 17,250,000 shares issued and outstanding at redemption value of 10.53 and 10.11 per share as of december 31, 2025 and 2024, respectively | 181,657,311 | |||
| Common stock | 466 | |||
| Accumulated deficit | -6,542,574 | |||
| Total shareholders' deficit | -6,542,108 | |||
| Total liabilities, class a ordinary shares subject to possible redemption, and shareholders' deficit | 181,696,776 | |||
Translational Development Acquisition Corp. (TDAC)
Translational Development Acquisition Corp. (TDAC)